AstraZeneca Pauses Leading Vaccine Candidate Trial

AstraZeneca's factory in Macclesfield, England. Image: Christopher Furlong/Getty
Image credit
AstraZeneca's factory in Macclesfield, England. Image: Christopher Furlong/Getty

AstraZeneca paused its Phase 3 COVID-19 vaccine trial, citing a suspected adverse reaction in one UK participant and an “abundance of caution.”

A standard review process triggered the hold, AstraZeneca said. It didn't share details but noted the illness could be unrelated to the vaccine: Illnesses in large trials happen by chance “but must be independently reviewed to check this carefully.”

The Impact: The pause in the trial of a front-runner vaccine candidate, developed with University of Oxford, is likely to slow the vaccine timeline, and potentially impact other clinical trials underway.

STAT

Comments +

0 comments

Post a Comment

Restricted HTML

  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Back to top